Multiomic Health
ABOUT.
MultiOmic Health discovers and develops life-changing precision medicines for metabolic syndrome-derived diseases. Metabolic syndrome refers to a set of lifestyle and age-related risk factors — dysglycemia, hypertension, dyslipidemia, obesity — that lead to multiple (and often concurrent) serious medical conditions such as atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver. This group of closely-related conditions constitutes the world’s costliest healthcare burden, consuming $2 trillion in global healthcare costs in 2019 (1.6 times more than cancer), a cost that is forecast to exceed $5.5 trillion by 2040.
Using our unique combination of deep longitudinal patient datasets, AI-enabled data science capabilities and experimental biology expertise, we identify patient subpopulations having their own distinct molecular-level disease drivers. We use these insights to originate and pursue our own therapeutic R&D programmes, each with the corresponding patient-stratifying biomarkers. This precision medicine approach enables shorter and smaller clinical trials with inherently higher success rates.
MultiOmic Health has established its own drug discovery and development pipeline with corresponding companion diagnostics. Approved drugs resulting from our therapeutics programmes will be marketed by pharmaceutical industry partners. We also commission laboratory service providers to implement our companion diagnostics as LDT and IVD tests.
TYPE 2
DIABETES
CHRONIC KIDNEY DISEASE
ATHEROSCLEROSIS
NON-ALCOHOLIC FATTY LIVER
OUR FOCUS.
In the near term, our work is focused on developing precision therapeutics for serious medical complications of diabetes including nephropathy, neuropathy, retinopathy and associated cardiovascular events.
We are investigating the underlying disease biology of these complications at the molecular level, using multiple omics modalities integrated with longitudinal clinical phenotyping.
The resulting insights will enable us to derive much more effective therapeutics and associated companion diagnostics optimised for specific patient subpopulations.
STATISTICS.
METABOLIC SYNDROME PANDEMIC
please view sidebar for data sources.
WHAT WE DO
MULTI Omic ANalysis.
GENOMICS
How someone's genes predispose disease and influence drug response
EPIGENOMICS
How ageing and external factors affect gene expression
PROTEOMICS
Which proteins are actually produced
METABOLOMICS
Which byproducts of metabolism are generated
UNDERSTANDING CHRONIC DISEASE BIOLOGY
EXPERTS IN THEIR FIELDS
OPERATING TEAM.
Robert Thong
Co-founder & CEO
30+ years in biopharma & healthcare, focusing on R&D management, B2B partnerships and value creation strategy. Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models
Celia Schell
CHIEF OPERATING OFFICER
14 years experience in clinical research at Novartis and ICON. Recently managed a global Phase III clinical trial of >7,000 cardiovascular patients across 43 countries
Michael Sierra
CHIEF SCIENTIFIC OFFICER
30+ years in drug discovery with LEO Pharma and GSK. Involved in 23 development candidates including 6 which became approved drugs.
Ariella Cohain
CHIEF TECHNOLOGY OFFICER
Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion
Rebecca Fairclough
SENIOR DIRECTOR
COLLABORATIVE R&D
10 years with AstraZeneca working with AI technologies and startups, repurposing initiatives and open innovation. Previously with Norgine in drug discovery and prior to that co-founded a startup spun out from academia
Valeryia Kuzmuk
ASSOCIATE DIRECTOR
TRANSLATIONAL SCIENCE
Award-winning renal biologist. Has taken a novel therapeutic from unvalidated target to development candidate for Phase I. Previously at a UK biotech managing drug discovery assays and preclinical development studies
Karina Gutheridge
ASSOCIATE DIRECTOR COMPUTATIONAL BIOLOGY
Experienced at analyzing and interpreting multi-omic patient and in vitro/in vivo data. Previously in the translational medicine data science team at Benevolent AI
Esra Berkol
CHIEF OF STAFF
Broad experience base of international collaborative activities. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Founded & exited own business
Andrew Parton
Associate DIRECTOR
DATA Science
Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research including journal papers on systems biology modeling of atherosclerosis
Henrietta Bull
PARTNERSHIPS
MANAGER
Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D
Becky Cripps
MANAGER
BUSINESS DEVELOPMENT
Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations
Heather Jackson
SENIOR BIOINFORMATICIAN
Experienced at analyzing high-dimensional omics datasets and building bioinformatics pipelines. Previously a postdoc at Imperial College London
Laura Mitchell
ASSOCIATE
MARKET PRODUCT SPECIALIST
Previously interned at Immunocore, AstraZeneca and the Wellcome Sanger Institute
Contact.
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company
Company #13246608
Epworth House
25 City Road, Shoreditch, London, EC1Y 1AA
info@multiomic.health